Matt Hall joined NCATS in 2015 as a biology group leader in the NCATS Chemical Genomics Center focusing on biochemical and cell-based assays for automated, small molecule, high-throughput screening. Current efforts are identifying therapeutic avenues for rare and drug-resistant cancers, devising adjuvant strategies for platinum-based chemotherapies and developing assays for understanding blood plasma drug metabolism. His group also develop assays for small-molecule target engagement, explore the role of glutathione peroxidase in cancer, and examine drug interactions with the blood-brain barrier.